- Record: found
- Abstract: found
- Article: not found
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Ian R Reid
1 ,
Jacques P Brown ,
Peter Burckhardt ,
Zebulun Horowitz ,
Peter Richardson ,
Ulrich Trechsel ,
Albert Widmer ,
Jean-Pierre Devogelaer ,
Jean-Marc Kaufman ,
Philippe Jaeger ,
Jean-Jacques Body ,
Maria Luisa Brandi ,
Johann Broell ,
Raffaele Di Micco ,
Andrea Riccardo Genazzani ,
Dieter Felsenberg ,
Joachim Happ ,
Michael J Hooper ,
Jochen Ittner ,
Georg Leb ,
Hans Mallmin ,
Timothy Murray ,
Sergio Ortolani ,
Alessandro Rubinacci ,
Maria Saaf ,
Goran Samsioe ,
Leon Verbruggen ,
Pierre J Meunier
Feb 28 2002
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored.